Report Sections

See All Reports

Coronavirus Infections (808) Severe Acute Respiratory Syndrome (560) Infection (466) Pneumonia (365) Communicable Diseases (197) Respiratory Distress Syndrome, Adult (178) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) (130) Syndrome (105) Virus Diseases (87) Pneumonia, Viral (82) Depression (65) Critical Illness (62) Anxiety Disorders (38) Respiratory Tract Infections (36) Cardiovascular Diseases (35) Emergencies (35) Stress, Psychological (31) Lung Injury (30) Neoplasms (30) Inflammation (29) Stress Disorders, Post-Traumatic (29) Wounds and Injuries (29) Hypoxia (28) Thrombosis (28) Diabetes Mellitus (26) Disease (25) Respiratory Tract Diseases (25) Stress Disorders, Traumatic (25) Depressive Disorder (24) Acute Kidney Injury (22) Disease Progression (22) Lung Diseases (22) Mental Disorders (21) Burnout, Psychological (19) Olfaction Disorders (19) Respiration Disorders (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Fibrosis (12) Arthritis, Rheumatoid (11) Influenza, Human (11) Rheumatic Diseases (11) Venous Thrombosis (11) Dyspnea (10) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Heart Failure (8) Infarction (8) Liver Diseases (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lung Diseases, Obstructive (7) Lymphopenia (7) Multiple Sclerosis (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Pulmonary Disease, Chronic Obstructive (6) Autoimmune Diseases (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Nervous System Diseases (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Adenoviridae Infections (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Colorectal Neoplasms (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypertension, Pulmonary (3) Ischemia (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Initiation and Maintenance Disorders (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Ageusia (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Bacteremia (2) Behcet Syndrome (2) Bipolar Disorder (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) (2) Dementia (2) Depressive Disorder, Major (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Eye Diseases (2) Fever (2) Fibromyalgia (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypersensitivity (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) (1) Common Cold (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronavirus Infect (1) (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) Developmental Disabilities (1) DiGeorge Syndrome (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal Neoplasms (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophies (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Reperfusion Injury (1) Resp (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D004417: Dyspnea

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (25)


Name (Synonyms) Correlation
drug1737 Knowledge, Attitude, Practice, Awareness, Preference Wiki 0.32
drug2178 No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups Wiki 0.32
drug2125 Nebulized administration of RLF-100 or Placebo Wiki 0.32
Name (Synonyms) Correlation
drug156 Additional and minimal collection of products of the human body carried out during a sample for standard of care Wiki 0.32
drug251 Antioxidation Therapy Wiki 0.32
drug3770 ensoETM device Wiki 0.32
drug1468 Hydrogen Oxygen Generator with Nebulizer Wiki 0.32
drug2914 SELF-BREATHE Wiki 0.32
drug3169 Standard-of-care Wiki 0.32
drug4019 specific exercise rehabilitation treatment Wiki 0.32
drug3769 electrolytes Wiki 0.32
drug3794 heat therapy Wiki 0.32
drug3757 diagnostic Wiki 0.32
drug3776 exercise training Wiki 0.32
drug3761 draw blood Wiki 0.32
drug380 BRII-196 Wiki 0.32
drug2722 RLF-100 (aviptadil) Wiki 0.22
drug967 Data Collection Wiki 0.22
drug2715 RECOP unit patient Wiki 0.22
drug2159 Nitric Oxide Wiki 0.16
drug864 Convalescent Plasma Wiki 0.06
drug333 Azithromycin Wiki 0.05
drug3138 Standard of Care Wiki 0.05
drug1472 Hydroxychloroquine Wiki 0.03
drug2448 Placebo Wiki 0.03

Correlated MeSH Terms (18)


Name (Synonyms) Correlation
D063806 Myalgia NIH 0.32
D017093 Liver Failure NIH 0.32
D001987 Bronchiectasis NIH 0.18
Name (Synonyms) Correlation
D003550 Cystic Fibrosis NIH 0.18
D000755 Anemia, Sickle Cell NIH 0.16
D055370 Lung Injury NIH 0.12
D017563 Lung Diseases, Interstitial NIH 0.08
D012127 Respiratory Distress Syndrome, Newborn NIH 0.08
D055371 Acute Lung Injury NIH 0.08
D012128 Respiratory Distress Syndrome, Adult NIH 0.07
D008171 Lung Diseases, NIH 0.07
D004630 Emergencies NIH 0.05
D011024 Pneumonia, Viral NIH 0.03
D011014 Pneumonia NIH 0.03
D007239 Infection NIH 0.03
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D003141 Communicable Diseases NIH 0.02
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (7)


Name (Synonyms) Correlation
HP:0002098 Respiratory distress HPO 1.00
HP:0003326 Myalgia HPO 0.32
HP:0001399 Hepatic failure HPO 0.32
Name (Synonyms) Correlation
HP:0002110 Bronchiectasis HPO 0.18
HP:0006515 Interstitial pneumonitis HPO 0.08
HP:0002088 Abnormal lung morphology HPO 0.07
HP:0002090 Pneumonia HPO 0.03

Clinical Trials

Navigate: Correlations   HPO

There are 10 clinical trials


1 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

NCT04290858
Conditions
  1. Coronavirus Infections
  2. Pneumonia, Viral
  3. Dyspnea
Interventions
  1. Drug: Nitric Oxide
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress

Primary Outcomes

Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

Measure: Reduction in the incidence of intubation and mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Mortality from all causes

Measure: Mortality

Time: 28 days

Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab

Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

Time: 7 days

Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).

Measure: Time to clinical recovery

Time: 28 days
2 Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19

Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or mechanical ventilation. Mortality rates as high as 80% have been reported among those who require mechanical ventilation, despite best available intensive care. Patients with moderate and severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized RLF-100 (aviptadil, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care vs. placebo + Standard of Care using an FDA 501(k) cleared mesh nebulizer. The primary outcome will be progression to in severity of COVID-19 (i.e. moderate progressing to to severe or critical OR severe progressing to critical) over 28 days. Secondary outcomes will include blood oxygenation as measured by pulse oximetry, dyspnea, exercise tolerance, and levels of TNFα IL-6 and other cytokines.

NCT04360096
Conditions
  1. SARS-CoV 2
  2. COVID
  3. ARDS
  4. ALI
  5. Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
  6. Dyspnea
Interventions
  1. Drug: RLF-100 (aviptadil)
  2. Drug: Placebo
  3. Device: Nebulized administration of RLF-100 or Placebo
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Sy Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: Progression to ARDS is defined as the need for mechanical ventilation

Measure: Progression to ARDS

Time: 28 days

Secondary Outcomes

Description: Blood PO2 as measured by pulse oximetry

Measure: Blood oxygenation

Time: 28 days

Description: 0 = no shortness of breath at all 0.5 = very, very slight shortness of breath = very mild shortness of breath = mild shortness of breath = moderate shortness of breath or breathing difficulty = somewhat severe shortness of breath = strong or hard breathing 7 = severe shortness of breath or very hard breathing 8 9 = extremely severe shortness of breath 10 = shortness of breath so severe you need to stop the exercise or activity

Measure: RDP Dsypnea Scale

Time: 28 days

Description: Distance walked in six minutes

Measure: Distance walked in six minutes

Time: 28 days
3 Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial

This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.

NCT04378712
Conditions
  1. Covid-19
  2. Hydrogen/Oxygen Mixed Gas
  3. Dyspnea
Interventions
  1. Device: Hydrogen Oxygen Generator with Nebulizer
  2. Other: Standard-of-care
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The proportion of patients with improved disease severity (by at least one scale) at day 2

Measure: The proportion of patients with improved disease severity at day 2

Time: from baseline to day 2

Description: The proportion of patients with improved disease severity (by at least one scale) at day 3

Measure: The proportion of patients with improved disease severity at day 3

Time: from baseline to day 3

Description: The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge

Measure: The proportion of patients with improved disease severity at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Secondary Outcomes

Description: The change from baseline in oxygen saturation at day 2.

Measure: The change from baseline in oxygen saturation at day 2.

Time: from baseline to day 2

Description: The change from baseline in oxygen saturation at day 3.

Measure: The change from baseline in oxygen saturation at day 3.

Time: from baseline to day 3

Description: The change from baseline in oxygen saturation at the day before hospital discharge.

Measure: The change from baseline in oxygen saturation at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in dyspnea scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in dyspnea scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in dyspnea scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2

Measure: The change from baseline in cough scale at day 2

Time: from baseline to day 2

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3

Measure: The change from baseline in cough scale at day 3

Time: from baseline to day 3

Description: The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge

Measure: The change from baseline in cough scale at the day before hospital discharge

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in chest pain scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in chest pain scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in chest pain scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.

Measure: The change from baseline in chest distress scale at day 2.

Time: from baseline to day 2

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.

Measure: The change from baseline in chest distress scale at day 3.

Time: from baseline to day 3

Description: The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.

Measure: The change from baseline in chest distress scale at the day before hospital discharge.

Time: up to 14 days (from baseline to the day before hospital discharge)
4 An International Observational Study of Outpatients With SARS-CoV-2 Infection

The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

NCT04385251
Conditions
  1. COVID
  2. COVID19
  3. SARS-CoV 2
  4. Dyspnea
Interventions
  1. Other: Data Collection
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.

Measure: Time to Hospitalization

Time: 28 days

Description: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.

Measure: Time to Expiration

Time: 28 days

Secondary Outcomes

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.

Measure: Rate of Death at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.

Measure: Rate of Death at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.

Measure: Rate of Death at 28 Days

Time: 28 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.

Measure: Rate of Hospitalization at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.

Measure: Rate of Hospitalization at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.

Measure: Rate of Hospitalization at 28 Days

Time: 28 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.

Measure: Participant Health at 7 Days

Time: 7 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.

Measure: Participant Health at 14 Days

Time: 14 days

Description: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.

Measure: Participant Health at 28 Days

Time: 28 days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 7 Days

Time: 7 Days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 14 Days

Time: 14 Days

Description: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.

Measure: Modified Borg Dyspnea Scale at 28 Days

Time: 28 Days
5 Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea

This research aims to improve our knowledge of the epidemiology of patients consulting in the COvid-19 Possible REspiratory Units (RECOP unit). Indeed, the epidemic linked to COVID-19 affects France and impacts its health system. The reception of all intermediate patients will be on the Emergency Structures (SU). Indeed, the French healthcare system centralizes unscheduled urgent care on the ER. The aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to SU or the diagnostic approach to respiratory difficulty may be carried out. A central issue of this diagnostic strategy will be to be rapid, since the diagnosis will have to be made in the context of significant flows, with a need to quickly refer patients to the most suitable downstream service, while limiting the risk contamination of caregivers and vulnerable patients if a COVID-19 + patient is admitted to an unsuitable service. However, virological tests do not currently allow rapid results for COVID-19. Research project of investigatory aims to develop a predictive model of the risk of being COVID-19 positive for patients admitted to the emergency room for acute dyspnea.

NCT04422587
Conditions
  1. Emergencies
Interventions
  1. Other: RECOP unit patient
MeSH:Dyspnea Emergencies
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: demographic variables, usual history and treatments, episode characteristics (symptomatology, evolution, treatment taken) and data from the initial clinical examination will be collected by doctor

Measure: Develop a predictive model of the risk of being COVID-19 for patients admitted to the emergency room for dyspnea

Time: inclusion day

Secondary Outcomes

Description: The COVID-19 virological condition will be taken with PCR tests on naso-pharyngeal samples or on sputum for patients taking

Measure: Describe the characteristics of patients admitted to reCOP units according to their virological status

Time: 30 days

Description: Virological status will be collected by a phone call at the patient

Measure: Virological status

Time: 30 days

Description: Mortality status will be collected by a phone call at the patient

Measure: Mortality status

Time: 30 days
6 Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study

Coronavirus disease 2019 (abbreviated "COVID- 19") is a pandemic respiratory disease that is caused by a novel coronavirus and was first detected in December 2019 in Wuhan, China. The disease is highly infectious, and its main clinical symptoms include fever, dry cough, fatigue, myalgia, and dyspnoea.1 In China, 18.5% of the patients with COVID-19 developed to the severe stage, which is characterized by acute respiratory distress syndrome, septic shock, difficult-to-tackle metabolic acidosis, and bleeding and coagulation dysfunction. After China, COVID-19 spread across the world and many governments implemented unprecedented measures like suspension of public transportation, the closing of public spaces, close management of communities, and isolation and care for infected people and suspected cases. The Malaysian government had enforced Movement Control Order (MCO) from 18th March to 4th May 2020 and henceforth Conditional Movement Control Order (CMCO) until 9th June 2020. The battle against COVID-19 is still continuing in Malaysia and all over the world. Due to the CMO and CMCO in the country, public and private universities have activated the e-learning mode for classes and as the government ordered, universities are closed and no face-to-face activities allowed. This has forced students of all disciplines including dentistry to stay at home which are wide-spread across Malaysia and shift to e- learning mode. To guarantee the final success for fight against COVID-19, regardless of their education status, students' adherence to these control measures are essential, which is largely affected by their knowledge, attitudes, and practices (KAP) towards COVID-19 in accordance with KAP theory. Once the restrictions are eased students have to come back and resume their clinical work in the campus. Hence, in this study we assessed the Knowledge, Attitude, and Practice (KAP) towards COVID-19 and the students preference for online learning.

NCT04449081
Conditions
  1. Acute Respiratory Distress Syndrome
  2. Corona Virus Infection
  3. Acute Lung Injury
  4. Fever
  5. Myalgia
  6. Cough
  7. Dyspnea
  8. Septic Shock
  9. Bleeding
Interventions
  1. Behavioral: Knowledge, Attitude, Practice, Awareness, Preference
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Myalgia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea Lung Injury
HPO:Dyspnea Myalgia Respiratory distress

Primary Outcomes

Description: KAP towards COVID-19 was assessed using validated questionnnaire

Measure: Knowledge, Attitude, Practice of dental students towards COVID-19

Time: 4 months

Secondary Outcomes

Description: Awareness level about Infection control to prevent COVID-19 transmission in clinics was assesed using a standardized questionnaire

Measure: Awareness level about Infection control to prevent COVID-19 transmission in clinics

Time: 4 months

Description: Preference towards online learning. was assessed using a standard questionnaire

Measure: Preference towards online learning.

Time: 4 months
7 Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study

The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.

NCT04505631
Conditions
  1. Covid19
  2. Dyspnea
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The presence of respiratory sequelae will be assessed by low dose thoracic tomodensitometry

Measure: Presence of respiratory sequelae

Time: 6 months after hospital discharge

Secondary Outcomes

Measure: Presence of respiratory sequelae on low dose thoracic tomodensitometry

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced vital capacity (FVC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced vital capacity (FVC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced expiratory volume in 1 second (FEV1, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Forced expiratory volume in 1 second (FEV1, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Tiffeneau-Pinelli index (FEV1/FVC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Total lung capacity (TLC, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Total lung capacity (TLC, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Residual volume (RV, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Residual volume (RV, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: RV/TLC ratio (%)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: RV/TLC ratio (%)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal inspiratory pressure (MIP, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal inspiratory pressure (MIP, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal expiratory pressure (MEP, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Maximal expiratory pressure (MEP, %)

Time: 3 months after hospital discharge

Description: Respiratory functional exploration

Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

Time: 6 months after hospital discharge

Description: Respiratory functional exploration

Measure: Diffusion capacity of the lungs for carbon monoxide (DLCO, %)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: pH

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: pH

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen partial pressure (PaO2, mmHg)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen partial pressure (PaO2, mmHg)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial carbon dioxide partial pressure (PaCO2, mmHg)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Bicarbonate concentration (mmol/L)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Bicarbonate concentration (mmol/L)

Time: 3 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen saturation (SaO2, %)

Time: 6 months after hospital discharge

Description: Arterial gasometry will be performed under ambient air and under oxygen

Measure: Arterial oxygen saturation (SaO2, %)

Time: 3 months after hospital discharge

Description: Six-minute walk test will be performed under ambient air and under oxygen

Measure: Six-minute walk test

Time: 6 months after hospital discharge

Description: Six-minute walk test will be performed under ambient air and under oxygen

Measure: Six-minute walk test

Time: 3 months after hospital discharge
8 Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon

Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom. The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table. The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4). The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.

NCT04522037
Conditions
  1. Patients Hospitalized in the Hospices Civils of Lyon
  2. COVID-19 Disease
  3. Moderate to Severe Dyspnea
  4. Without Resuscitation Objective Management
Interventions
  1. Other: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
MeSH:Dyspnea
HPO:Dyspnea Respiratory distress

Primary Outcomes

Description: The respiratory rate is analyzed at Hour 0 and Hour 12 by a scope.

Measure: Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment

Time: Hour 0 and Hour 12 after initiation of morphinic treatment
9 Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU

Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause. Resuscitation is associated with many causes of dyspnea, including initial distress, mechanical ventilation, or after-effects following the pathology and its management. Respiratory distress is the most severe form of impaired lung function. It is the first cause of hospitalization in intensive care. This distress, indicative of the failure of the respiratory system, is always severe and potentially fatal. It therefore constitutes an absolute therapeutic emergency. Dyspnea is often the revealing symptom of the condition and the urgency surrounding its management is an additional factor of concern for the patient. As a result, dyspnea is a pejorative element associated with severity or even death.

NCT04569266
Conditions
  1. Dyspnea
Interventions
  1. Other: specific exercise rehabilitation treatment
MeSH:Pneumonia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress

Primary Outcomes

Description: Multidimensional Dyspnea Profile (MDP) scale assessment of dyspnea

Measure: Evaluate the effect of exercise rehabilitation on post-ICU dyspnea

Time: Day 1

Description: Multidimensional Dyspnea Profile (MDP) scale assessment of dyspnea

Measure: Evaluate the effect of exercise rehabilitation on post-ICU dyspnea

Time: 3 Months

Secondary Outcomes

Description: Assessment of dyspnea on the Modified Medical Research Council (mMRC) scale

Measure: Evaluate the effect of exercise rehabilitation on functional dyspnea

Time: Day 1

Description: Assessment of dyspnea on the Modified Medical Research Council (mMRC) scale

Measure: Evaluate the effect of exercise rehabilitation on functional dyspnea

Time: 3 Months

Description: Short-Form Quality of Life Assessment (SF-12)

Measure: Evaluate the effect of stress rehabilitation on quality of life

Time: Day 1

Description: Short-Form Quality of Life Assessment (SF-12)

Measure: Evaluate the effect of stress rehabilitation on quality of life

Time: 3 Months
10 A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

NCT04574050
Conditions
  1. Cancer
  2. COPD
  3. Asthma
  4. Bronchiectasis Adult
  5. Interstitial Lung Disease
  6. Cystic Fibrosis
  7. Chronic Heart Failure
  8. Sickle Cell Disease
  9. Renal Failure
  10. Liver Failure
  11. Post COVID-19
  12. Dyspnea
Interventions
  1. Other: SELF-BREATHE
MeSH:Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Bronchiectasis Lung Diseases, Interstitial Anemia, Sickle Cell
HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Dyspnea Hepatic failure Interstitial pneumonitis Respiratory distress

Primary Outcomes

Description: The number of patients recruited into this study over a 12-month period

Measure: Feasibility: the number of patients recruited into this study over a 12-month period

Time: 12 months

HPO Nodes


HP:0002094: Dyspnea
Genes 438
TLL1 MAT2A TRNK DSP CHRNA1 LMNA CSPP1 TRPV6 AIFM1 NPM1 ZBTB16 EFTUD2 TGFBR2 LAMA3 SFTPA1 SH2B3 IKZF1 ND1 DNAJB6 BTNL2 COPA KCNJ6 USP9X GAA MEGF10 KRT16 GATA6 GATA4 FGFR2 APOB CASR MYL3 ZIC3 NKX2-1 PLEC PURA AIMP2 DCTN1 DOK7 KCNA1 SCNN1B SCN4A CDC6 LAMB2 DYNC2LI1 RARA ALAS2 VAPB IRF5 PMM2 STT3B ADNP SCO2 MUSK MYH6 ABCA3 TSC1 ATRX FOXF1 CHRNA1 ORC4 FOXP3 TERC USP9X CAV1 ND4 CBL COLQ COL2A1 EPHB4 FGFR1 NOD2 STAT5B MAPT COL2A1 TARDBP CREBBP FBP1 ACTA2 BMPER SLC35A1 SOX9 MATR3 CCR6 PRRT2 MFAP5 GLA RELN CHRNE AK9 SLC5A7 CHRNB1 COL13A1 CSF2RB SCN4A DISC1 TRNV PRPH FGFR2 ACVRL1 PYGM TRMU RNF13 CHRNE NDUFB11 SLC25A4 DNA2 NAGS ACADVL MRPL3 VPS33A TRPM4 NGLY1 MYH11 NEFH TRIP11 CRELD1 SCN5A SCO2 CAV1 ND5 ORC6 PUF60 SMAD4 SMPD1 CYB5R3 GATA6 XYLT1 KAT6A KIF20A EDA SNRPN RPS28 GNAI3 CCNF TTN CDC45 ZMPSTE24 STN1 PRKCSH SBDS TRNN VCP MYL2 VCP TBX20 CSF2RA ND3 TRNK GBA ISCU TGFB2 NUMA1 GATA4 TERT SCNN1G MMACHC SFTPC ATP11A NKX2-5 HBB EIF2AK4 SPP1 CITED2 LDLRAP1 MMAA MYBPC3 ERBB4 DAO ZFPM2 ALMS1 CHRND ORC1 PURA SCN4A TUBB4A SFTPC ALDH7A1 LDLR DNASE1L3 IFT81 MUC5B MARS1 SSR4 EPHA4 CHCHD10 CHMP2B ENG MPC1 NPPA CCN2 ARX MGME1 DPM2 TSC2 PLCB4 AGRN TAF15 NUP214 TRIP11 NKX2-5 TSC2 MMUT PCSK9 OPTN POLG2 JPH2 DBH SCN1B TERT SLC18A3 FOXE3 TRNL1 RTEL1 PRKG1 OTX2 NABP1 DNAAF3 DPM2 DNAJC21 NAGS GALC SFTPB LIFR TNNT2 RUNX2 GLE1 HLCS ACTC1 VAMP1 TRNE BMPR2 ADAMTS13 ND2 UNC13A SLC25A1 ELN SFTPA2 TBK1 GATA6 SFTPB SCNN1A SERPINA1 PFN1 RAPSN LYRM4 CHRND MYH11 CRLF1 EOMES SLC2A10 NDUFB8 GBA MMUT POMT1 COQ7 ERF VCL UBE3B ETFDH SCN5A PON2 CFTR FLNC SDCCAG8 WIPF1 PARN HCCS BCOR GYG1 LAMC2 RRM2B ITGA3 GATA6 GTPBP3 FIG4 NEB TWNK STAT5B SFTPC SURF1 LTBP3 CSF2RB COL1A2 ABCA3 TBC1D24 GAA STAT4 SIK1 C9ORF72 DNA2 MUC5B TK2 SRSF2 TRNS1 DPP9 SMAD3 CITED2 CFAP410 FLNC STAT3 TNNI3 PRKAR1A CHRNE LOX TNNC1 TRAK1 ORC6 CYB5R3 CHRNB1 EDN1 FAM20C PON1 HNRNPA1 FBP1 HBB POLG STT3B DMPK SLC12A3 TRNE FBN1 SETBP1 NDUFAF3 ATXN2 PRRX1 TRNW ETFB RNU4ATAC SFTPC CNTNAP1 HLA-B CHAT PIGT TSC1 STX16 CLCNKB PGM1 CDT1 COX7B SLC25A1 B3GALT6 RPS26 IRF2BP2 TRMT5 TET2 ASXL1 ABCG5 WAS LGI4 PSAP PNKD SURF1 LRP4 PRRX1 TET2 GLT8D1 MGME1 ASAH1 DHX16 SRP54 GBA LAMB3 MYO9A MMAB IL1RN DSC2 ACADM IRAK1 RUNX1 TGFBR1 CYB5A COL13A1 ANG GNAS GMNN KLHL7 TBX20 ABCA3 ANXA11 NDUFS2 EPOR IFT52 UBQLN2 SFTPA2 FAM13A PON3 SLC52A3 KRT17 KRT6A ADCY6 HLA-DRB1 TET2 BMPER CPT2 MYLK PML MYPN TGFB3 AGRN SLC25A3 TBX4 FIP1L1 JAK2 KRT6B NEK1 SYT2 TBL1XR1 TREM2 GNAS ND6 FGFR2 EP300 MAPT ORC1 PPARGC1A DPM1 FGFR2 SQSTM1 HLA-DRB1 SOD1 HLA-DRB1 NKX2-1 TLL1 SNAP25 GNAS TERT FUS ATP6 ABCG8 NR2F2 COA8 ETFA VPS33A SERPING1 BTNL2 CHAT PRKAR1A
Protein Mutations 0
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0002094: Dyspnea
Genes 438
TLL1 MAT2A TRNK DSP CHRNA1 LMNA CSPP1 TRPV6 AIFM1 NPM1 ZBTB16 EFTUD2 TGFBR2 LAMA3 SFTPA1 SH2B3 IKZF1 ND1 DNAJB6 BTNL2 COPA KCNJ6 USP9X GAA MEGF10 KRT16 GATA6 GATA4 FGFR2 APOB CASR MYL3 ZIC3 NKX2-1 PLEC PURA AIMP2 DCTN1 DOK7 KCNA1 SCNN1B SCN4A CDC6 LAMB2 DYNC2LI1 RARA ALAS2 VAPB IRF5 PMM2 STT3B ADNP SCO2 MUSK MYH6 ABCA3 TSC1 ATRX FOXF1 CHRNA1 ORC4 FOXP3 TERC USP9X CAV1 ND4 CBL COLQ COL2A1 EPHB4 FGFR1 NOD2 STAT5B MAPT COL2A1 TARDBP CREBBP FBP1 ACTA2 BMPER SLC35A1 SOX9 MATR3 CCR6 PRRT2 MFAP5 GLA RELN CHRNE AK9 SLC5A7 CHRNB1 COL13A1 CSF2RB SCN4A DISC1 TRNV PRPH FGFR2 ACVRL1 PYGM TRMU RNF13 CHRNE NDUFB11 SLC25A4 DNA2 NAGS ACADVL MRPL3 VPS33A TRPM4 NGLY1 MYH11 NEFH TRIP11 CRELD1 SCN5A SCO2 CAV1 ND5 ORC6 PUF60 SMAD4 SMPD1 CYB5R3 GATA6 XYLT1 KAT6A KIF20A EDA SNRPN RPS28 GNAI3 CCNF TTN CDC45 ZMPSTE24 STN1 PRKCSH SBDS TRNN VCP MYL2 VCP TBX20 CSF2RA ND3 TRNK GBA ISCU TGFB2 NUMA1 GATA4 TERT SCNN1G MMACHC SFTPC ATP11A NKX2-5 HBB EIF2AK4 SPP1 CITED2 LDLRAP1 MMAA MYBPC3 ERBB4 DAO ZFPM2 ALMS1 CHRND ORC1 PURA SCN4A TUBB4A SFTPC ALDH7A1 LDLR DNASE1L3 IFT81 MUC5B MARS1 SSR4 EPHA4 CHCHD10 CHMP2B ENG MPC1 NPPA CCN2 ARX MGME1 DPM2 TSC2 PLCB4 AGRN TAF15 NUP214 TRIP11 NKX2-5 TSC2 MMUT PCSK9 OPTN POLG2 JPH2 DBH SCN1B TERT SLC18A3 FOXE3 TRNL1 RTEL1 PRKG1 OTX2 NABP1 DNAAF3 DPM2 DNAJC21 NAGS GALC SFTPB LIFR TNNT2 RUNX2 GLE1 HLCS ACTC1 VAMP1 TRNE BMPR2 ADAMTS13 ND2 UNC13A SLC25A1 ELN SFTPA2 TBK1 GATA6 SFTPB SCNN1A SERPINA1 PFN1 RAPSN LYRM4 CHRND MYH11 CRLF1 EOMES SLC2A10 NDUFB8 GBA MMUT POMT1 COQ7 ERF VCL UBE3B ETFDH SCN5A PON2 CFTR FLNC SDCCAG8 WIPF1 PARN HCCS BCOR GYG1 LAMC2 RRM2B ITGA3 GATA6 GTPBP3 FIG4 NEB TWNK STAT5B SFTPC SURF1 LTBP3 CSF2RB COL1A2 ABCA3 TBC1D24 GAA STAT4 SIK1 C9ORF72 DNA2 MUC5B TK2 SRSF2 TRNS1 DPP9 SMAD3 CITED2 CFAP410 FLNC STAT3 TNNI3 PRKAR1A CHRNE LOX TNNC1 TRAK1 ORC6 CYB5R3 CHRNB1 EDN1 FAM20C PON1 HNRNPA1 FBP1 HBB POLG STT3B DMPK SLC12A3 TRNE FBN1 SETBP1 NDUFAF3 ATXN2 PRRX1 TRNW ETFB RNU4ATAC SFTPC CNTNAP1 HLA-B CHAT PIGT TSC1 STX16 CLCNKB PGM1 CDT1 COX7B SLC25A1 B3GALT6 RPS26 IRF2BP2 TRMT5 TET2 ASXL1 ABCG5 WAS LGI4 PSAP PNKD SURF1 LRP4 PRRX1 TET2 GLT8D1 MGME1 ASAH1 DHX16 SRP54 GBA LAMB3 MYO9A MMAB IL1RN DSC2 ACADM IRAK1 RUNX1 TGFBR1 CYB5A COL13A1 ANG GNAS GMNN KLHL7 TBX20 ABCA3 ANXA11 NDUFS2 EPOR IFT52 UBQLN2 SFTPA2 FAM13A PON3 SLC52A3 KRT17 KRT6A ADCY6 HLA-DRB1 TET2 BMPER CPT2 MYLK PML MYPN TGFB3 AGRN SLC25A3 TBX4 FIP1L1 JAK2 KRT6B NEK1 SYT2 TBL1XR1 TREM2 GNAS ND6 FGFR2 EP300 MAPT ORC1 PPARGC1A DPM1 FGFR2 SQSTM1 HLA-DRB1 SOD1 HLA-DRB1 NKX2-1 TLL1 SNAP25 GNAS TERT FUS ATP6 ABCG8 NR2F2 COA8 ETFA VPS33A SERPING1 BTNL2 CHAT PRKAR1A
Protein Mutations 0
SNP 0

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook